Copolymer 1: From basic research to clinical application

Cellular and Molecular Life Sciences

Volumn 53, Issue 1, 1997, Pages 24-28

  Teitelbaum, D ^a   Arnon, R ^a   Sela, M ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Autoimmunity; Cop 1; Copaxone; Experimental allergic encephalomyelitis; Multiple sclerosis

Indexed keywords

GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; DRUG PROTEIN BINDING; HELPER CELL; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MOUSE; NONHUMAN; RECURRENCE RISK; SHORT SURVEY; T LYMPHOCYTE ACTIVATION;

ANIMALS; CLINICAL TRIALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PEPTIDES; POLYMERS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

ANIMALIA;

EID: 0030799763     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000576     Document Type: Short Survey

References (22)

1. Bernard C. C. A. and Kerlero de Rosbo N. (1992) Multiple sclerosis: an autoimmune disease of multifunctional etiology. Curr. Opin. Immunol. 4: 760-765
2. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R. and Sela M. (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1: 242-248
3. Sela M., Arnon R. and Teitelbaum D. (1990) Suppressive activity of Cop 1 in EAE and its relevance to multiple sclerosis. Bull. Inst. Pasteur 88: 303-314
4. Keith A. B., Arnon R., Teitelbaum D., Caspary E. A. and Wisniewski H. M. (1979) The effect of Cop 1, a synthetic polypeptide on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J. Neurol. Sci. 42: 267-274
5. Teitelbaum D., Fridkis-Hareli M., Arnon R. and Sela M. (1996) Copolymer 1 inhibits the onset of chronic relapsing experimental autoimmune encephalomyelitis and interferes with T cell responses to encephalitogenic peptides of myelin proteolipid protein. J. Neuroimmunol. 64: 209-217
6. Ben-Nun A., Mendel I., Bakimer R., Fridkis-Hareli M., Teitelbaum D., Arnon R. et al. (1996) The autoimmune reactivity to myelin oligodendrocyte glycoprotein [MOG] in multiple sclerosis is potentially pathogenic: effect of copolymer-1 on MOG-induced disease. J. Neurol. 243 (Suppl.): S14-S22
7. Teitelbaum D., Aharoni R., Sela M. and Arnon R. (1991) Cross reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc. Natl. Acad. Sci. USA 88: 9528-9532
8. Webb C., Teitelbaum D., Arnon R. and Sela M. (1993) In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur. J. Immunol. 3: 273-279
9. Webb C., Teitelbaum D., Herz A., Arnon R. and Sela M. (1976) Molecular requirements involved in suppression of EAE by basic copolymers of amino acids. Immunochem. 13: 333-337
10. Lando Z., Teitelbaum D. and Arnon R. (1979) Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J. Immunol. 132: 2156-2160
11. Aharoni R., Teilelbaum D. and Arnon R. (1993) T-suppressor hybridomas and IL-2 dependent lines induced by copolymer 1 or by spinal cord homogenate downregulate experimental allergic encephalomyelitis. Eur. J. Immunol. 23: 17-25
12. Aharoni R., Teitelbaum D., Sela M. and Arnon R. (1996) Copolymer 1 induces suppressor T-cells of the Th2 type. J. Neurol. 243 (Suppl. 2): S17
13. Teitelbaum D., Aharoni R., Arnon R. and Sela M. (1988) Specific inhibition of T cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc. Natl. Acad. Sci. USA 85: 9724-9728
14. Teitelbaum D., Milo R., Arnon R. and Sela M. (1992) Synthetic copolymer 1 inhibits human T cell lines specific for myelin basic protein. Proc. Natl. Acad. Sci 89: 137-141
15. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O. J. et al. (1994) Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity. Proc. Natl. Acad. Sci. USA 91: 4872-4876
16. Fridkis-Hareli M., Teitelbaum D. and Kerllero de Rosbo N. (1994) Synthetic Copolymer 1 inhibits the binding of MBP, PLP and MOG peptides to class II major histocompatibility complex molecules on antigen presenting cells. J. Neurochem. 63, Suppl. I: S61
17. Al-Sabbagh A., Miller A., Santos L. M. B. and Weiner H. L. (1994) Antigen-driven tissue specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur. J. Immunol. 24: 2104-2109
18. Lehmann P. V., Sercarz E. E., Forsthuber T., Dayan C. M. and Gaman G. (1993) Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunology Today 14: 203-208
19. Bornstein M. B., Miller A., Slagle S., Weitzmann M., Wassertheil-Smoller S., Spada V. et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New Eng. J. Med. 317: 408-414
20. Bornstein M. B., Miller A., Slagle S., Weitzmann M., Dexler E., Keilson M. et al. (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41: 533-539
21. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lisak R. P. et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenler double blind, placebo-controlled trial. Neurology 1: 65-70
22. Johnson K. P. (1996) Effect of copolymer 1 therapy on multiple sclerosis relapse rate and neurologic disability. J. Neurol. 243 (Suppl. 2): S32